🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

✨ Practice-changing for gallbladder cancer? A randomized phase 3 trial from 🇮🇳 evaluated NACTRT vs NACT in locally advanced GBC (T3/T4, N1, liver infiltration). Results: ✂️ R0 resection: 51.6% (NACTRT) vs 29.7% (NACT) p=0.01 ⏳ Median OS: 21.8 vs 10.1 mo HR: 0.56 (95% CI

👀 NEW Paper Systemic rx ⬆️ in PSMA-staged high risk prostate ca - is RT+ADT good enough?? Congrats Ashesh!👏🏼 OPEN ACCESS 👇 nature.com/articles/s4139… Builds on #ESTRO2025 debate ☢️ vs💊 for high risk prostate ca by Vedang Murthy Check out new trial RELAX on this Q! 🤩

📢 New publication alert from Head & Neck team TMC Radiation Oncology! Unique data on 83 second primary malignancies (SPMs) from a 900-patient RCT in HNSCC shows encouraging survival with aggressive multimodality salvage, including surgery. doi.org/10.1016/j.rado…

Watch this space!! Reena Engineer #POLCAGB #ASCO25

Is RT and ADT Good Enough in PSMA-Staged High-Risk Prostate Cancer? - Priyamvada Maitre (Priyamvada Maitre) Vedang Murthy oncodaily.com/insight/priyam… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ProstateCancer #RT #ADT #PSMA CancerWorld

View from ⁦Tata Memorial Hospital⁩ today afternoon. Never seen Mumbai like this in the “summer month” of May!!

The 2001 The Nobel Prize laureate Prof. Sir Paul Nurse for his groundbreaking work on the cell cycle, will deliver a talk on ‘Controlling the Cell Cycle’ on 29.5 at 2.30 pm Tata Memorial Hospital. You can catch it live streamed on our YT channel as well! DAE India  youtube.com/@TataMemorialC…

TMC Radiation Oncology residents, check this out!

Head & neck reconstruction is not only about replacing what’s lost; it’s about precision, function & quality of life Join "From Reconstruction to Restoration", Conference & workshop on dental implantology in head & neck cancer 📌ACTREC-TMC 📅 21.6.25 🔗 tinyurl.com/yacxxtpz

RTOG 0920 revisited 📢 Our opinion in Frontiers - Oncology frontiersin.org/journals/oncol… sarbani ghosh-laskar Shwetabh Sinha Anuj Kumar TMC Radiation Oncology

TMC Radiation Oncology Reena Engineer Very cool! GB management has come such a long way since I graduated training. TMC RO is awesome ♥️

#1DayToGo TMC NCG Navya at #ASCO2025 validating the Navya Earthshot - An AI Solution for Decentralizing Guidelines Based Cancer Care. Deepest gratitude to our first author Dr.Umesh Mahantshetty for leading this comprehensive study. @tatamemorial @cancergridindia ACT ASCO

Phase III RCT Alert ⚠️ POLCAGB In locally advanced gallbladder cancer; ✅ Neoadjuvant CRT doubled median OS vs CT alone (21.8 vs 10.1 mo) ✅ Improved R0 resection (51.6% vs 29.7%) #ASCO2025 asco.org/abstracts-pres…

TMC Radiation Oncology at #ASCO2025 #1 Dr Siddhartha Laskar was an invited faculty at #ASCO2025’s educational session on Pelvic Sarcomas, a vibrant hour of multidisciplinary insights & debates on treatment challenges and outcomes Kudos to Dr Laskar for representing TMC Radiation Oncology!

POLCAGB!! Kudos for a wonderful presentation Reena Engineer TMC Radiation Oncology ASCO #ASCO25

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

Dr Reena Engineer from TMC Radiation Oncology presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 Addition of NACRT to NACT shows ✅Better response to Neoadjuvant Rx ✅Higher R0 resection rates ✅Higher EFS (4.9 Vs 10.6 mos) ✅Higher OS (10.1 Vs 21.8 mos)

TMC randomized trial in locally advanced #GBC: 🧪 Preop chemoradiation (CRT) vs chemo (NACT) 📊 CRT → ✅ ORR 74% vs 35% ✅ CR 43% vs 10% ✅ PD 20% vs 44% 🧬 OS benefit: ⏳ mOS 21.8 vs 10.1 mo 🎯 HR 0.53 (p = 0.003) 🧩 5-yr OS 29% vs 17% 🎯 CRT better downstaging → better

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)